Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health · Aging Research (93.866)
Publicada 4 dic 2024 · Quedan aproximadamente 13 meses
En pocas palabras
Resumen aún no disponible en español; se muestra en inglés.
The National Institutes of Health funds pre-clinical and early-stage clinical development of drug candidates to prevent, slow, or treat Alzheimer's disease, including chemistry, animal testing, biomarker development, and initial human trials. Eligible applicants are primarily U.S. based institutions including universities, nonprofits, companies, and government agencies, with awards up to 1.5 million US dollars and applications due by 5 November 2027.
Un resumen generado del texto del donante; la redacción original figura más abajo.
Resumen
Texto original del donante (inglés)
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone…
Extracto de la página del donante. El texto completo, los anexos y los formularios están en la convocatoria original.
Quién puede presentar una solicitud
- Institución académica o de investigación
- ONG / sociedad civil
- Empresa privada
- Organismo gubernamental
- Organización comunitaria
Elegibilidad y condiciones
Mostrar el texto de elegibilidad de la fuente · Texto original del donante (inglés)
Applicant types: Native American tribal organizations (other than Federally recognized tribal governments); Independent school districts; Private institutions of higher education; Public and State controlled institutions of higher education; State governments; Small businesses; City or township governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Special district governments
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.